Immunotherapy for a Cancer-Free Future

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Our Approach

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

View pipeline

Meet our leadership team

Scancell has a bold ambition: to deliver and develop immunotherapies for a cancer free future. Our leadership team combines experienced and talented people who are committed to advancing our clinical programmes and translating innovative science for patient benefit.

Find out more